DD301364A7 - Verfahren zur Bestimmung von antinukleären Antikörpern - Google Patents

Verfahren zur Bestimmung von antinukleären Antikörpern Download PDF

Info

Publication number: DD301364A7
Authority: DD; German Democratic Republic
Prior art keywords: antinuclear antibodies; determination; antinuclear; immunoassay; cell nuclei
Prior art date: 1990-04-19

Application number

DD339884A

Other languages

German (de)

English (en)

Original Assignee

Berlin Buch Klinikum

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-19

Filing date

1990-04-19

Publication date

1992-12-10

1990-04-19 Application filed by Berlin Buch Klinikum filed Critical Berlin Buch Klinikum

1990-04-19 Priority to DD339884A priority Critical patent/DD301364A7/de

1991-04-18 Priority to DE59108789T priority patent/DE59108789D1/de

1991-04-18 Priority to EP19910250107 priority patent/EP0453060B1/fr

1992-12-10 Publication of DD301364A7 publication Critical patent/DD301364A7/de

Links

230000003460 anti-nuclear Effects 0.000 title claims abstract description 32
238000000034 method Methods 0.000 title claims abstract description 19
210000003855 cell nucleus Anatomy 0.000 claims abstract description 12
238000003018 immunoassay Methods 0.000 claims abstract description 9
238000001514 detection method Methods 0.000 claims abstract description 8
239000007790 solid phase Substances 0.000 claims abstract description 7
230000027455 binding Effects 0.000 claims abstract description 5
210000001124 body fluid Anatomy 0.000 claims abstract description 4
239000010839 body fluid Substances 0.000 claims abstract description 4
239000000872 buffer Substances 0.000 claims description 11
210000004940 nucleus Anatomy 0.000 claims description 9
102000004190 Enzymes Human genes 0.000 claims description 7
108090000790 Enzymes Proteins 0.000 claims description 7
108060003951 Immunoglobulin Proteins 0.000 claims description 5
102000018358 immunoglobulin Human genes 0.000 claims description 5
210000004185 liver Anatomy 0.000 claims description 5
238000005119 centrifugation Methods 0.000 claims description 3
210000001822 immobilized cell Anatomy 0.000 claims description 3
230000003196 chaotropic effect Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
230000002999 depolarising effect Effects 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
230000009870 specific binding Effects 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
239000003153 chemical reaction reagent Substances 0.000 claims 1
210000002966 serum Anatomy 0.000 abstract description 8
239000004793 Polystyrene Substances 0.000 abstract description 5
229920002223 polystyrene Polymers 0.000 abstract description 5
102000019040 Nuclear Antigens Human genes 0.000 abstract description 4
108010051791 Nuclear Antigens Proteins 0.000 abstract description 4
238000010166 immunofluorescence Methods 0.000 abstract description 3
208000027932 Collagen disease Diseases 0.000 abstract description 2
208000025747 Rheumatic disease Diseases 0.000 abstract description 2
230000000274 adsorptive effect Effects 0.000 abstract description 2
210000002919 epithelial cell Anatomy 0.000 abstract description 2
210000005229 liver cell Anatomy 0.000 abstract 1
241000700159 Rattus Species 0.000 description 5
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
208000003250 Mixed connective tissue disease Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
244000309466 calf Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000005497 microtitration Methods 0.000 description 1
238000005375 photometry Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
239000000758 substrate Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

DD339884A 1990-04-19 1990-04-19 Verfahren zur Bestimmung von antinukleären Antikörpern DD301364A7 (de)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
DD339884A DD301364A7 (de)	1990-04-19	1990-04-19	Verfahren zur Bestimmung von antinukleären Antikörpern
DE59108789T DE59108789D1 (de)	1990-04-19	1991-04-18	Verfahren zur Bestimmung von antinukleären Antikörpern
EP19910250107 EP0453060B1 (fr)	1990-04-19	1991-04-18	Méthode pour déterminer des anti-corps anti-nucléaires

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DD339884A DD301364A7 (de)	1990-04-19	1990-04-19	Verfahren zur Bestimmung von antinukleären Antikörpern

Publications (1)

Publication Number	Publication Date
DD301364A7 true DD301364A7 (de)	1992-12-10

Family

ID=5617931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD339884A DD301364A7 (de)	1990-04-19	1990-04-19	Verfahren zur Bestimmung von antinukleären Antikörpern

Country Status (3)

Country	Link
EP (1)	EP0453060B1 (fr)
DD (1)	DD301364A7 (fr)
DE (1)	DE59108789D1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2864624A1 (fr) *	2003-12-24	2005-07-01	Inodiag	Methode de diagnostic serologique des maladies infectieuses par immunodetection d'antigene microbien comprenant le controle de reaction faussement positive ou negative
ATE439594T1 (de) *	2003-12-24	2009-08-15	Inodiag	Verfahren zur serologischen diagnose und bestimmung des immunisierungszustands unter einschluss verschiedener kontrollen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3997657A (en) *	1973-10-15	1976-12-14	American Cyanamid Company	Dry slide reagent employed in immunofluorescent test for detection of human antinuclear factor
EP0206779A1 (fr)	1985-06-21	1986-12-30	Modern Diagnostics, Inc.	Détection des anticorps antinucléaires
DD241789A1 (de) *	1985-10-16	1986-12-24	Univ Berlin Humboldt	Selektives adsorbens zur bindung von immunkomplexen
DD262672A1 (de)	1986-04-02	1988-12-07	Akad Wissenschaften Ddr	Verfahren zur immobilisierung und zum nachweis von biomakromolekuelen, biologischen materialien und niedermolekularen verbindungen
EP0335293A3 (fr)	1988-03-30	1990-09-12	Hoechst Japan Limited	Procédé pour préparer un élément analytique pour la détermination d'anticorps anti-nucléaire

1990
- 1990-04-19 DD DD339884A patent/DD301364A7/de unknown
1991
- 1991-04-18 DE DE59108789T patent/DE59108789D1/de not_active Expired - Fee Related
- 1991-04-18 EP EP19910250107 patent/EP0453060B1/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE59108789D1 (de)	1997-08-28
EP0453060A3 (en)	1991-11-27
EP0453060B1 (fr)	1997-07-23
EP0453060A2 (fr)	1991-10-23

Legal Events

Date	Code	Title	Description
1992-05-07	NAA	Public notice for inspection of patent application
2004-04-28	IF04	In force in the year 2004	Expiry date: 20100420

Publication	Publication Date	Title
DE69424700T2 (de)	2000-11-09	Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis
DE69626026T2 (de)	2004-01-22	Differentialtest für ulzerative kolitis, primäre sklerosierende cholangitis und autoimmun-hepatitis vom type 1.
EP0544869B1 (fr)	1996-01-10	Procede immunologique de depistage d'anticorps dans des liquides biologiques et kit de mise en oeuvre du procede
Nyland et al.	1978	Guillain‐Barré syndrome: Demonstration of antibodies to peripheral nerve tissue
BRPI0611866A2 (pt)	2010-10-05	dispositivo de imunoensaio e método para imobilizar cardiolipina imunorreativa
DE69725606T2 (de)	2004-08-05	Methoden für die diagnose von allergischen atemwegsaspergillosen
DE69001972T2 (de)	1993-09-23	Mittel zum nachweis von gehirnkrankheiten in zusammenhang mit nervenscheidenmarkzerstoerung, insbesondere sklerosis multiplex.
DE69616563T2 (de)	2002-07-18	Verfahren zur diagnose von autoimmunerkrankungen
WO2004040310A1 (fr)	2004-05-13	Dispositif et methode permettant de diagnostiquer une treponematose
DE19920704C1 (de)	2000-08-31	Verwendung eines gegen Harn-Trypsin-Inhibitors gerichteten Antikörpers für die Diagnose des Ausbruchs von AIDS
DE3685818T2 (de)	1993-01-14	Immunkomplextestverfahren.
WO2001014877A2 (fr)	2001-03-01	Procede de diagnostic du syndrome de sjogren
DD301364A7 (de)	1992-12-10	Verfahren zur Bestimmung von antinukleären Antikörpern
DE69509357T2 (de)	1999-11-18	Marker für entzündungskrankheiten und/oder pathologien, die auf einer autoimmunreaktion beruhen
DE69431051T2 (de)	2003-03-13	Verfahren zur bestimmung der diabetesanfälligkeit bei asymptomatischen patienten
DE68921277T2 (de)	1995-10-12	Bestimmung von Getreidepflanzen.
DE69625048T2 (de)	2003-09-25	Kompetitiver bindungstest zur bestimmung von antigenen auf blutplättchen
DE69621915T2 (de)	2003-01-23	Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen
EP0554657B1 (fr)	1998-12-16	Méthode pour la détermination d'antigènes ou d'anticorps dans la présence d'une complexe immunologique
EP0776906A2 (fr)	1997-06-04	Peptides de l'antigène Sm-D et leur utilisation notamment pour le diagnostic du lupus erythémateux disséminé
EP0763740A1 (fr)	1997-03-19	Procédé de détermination des phénomènes autoimmmunes
WO1989007764A1 (fr)	1989-08-24	Procede de recherche d'anticorps specifiques contre les maladies rhumatismales, en particulier la polyarthrite chronique, ainsi que reactif approprie
EP0491310A2 (fr)	1992-06-24	Procédé pour la détermination d'anticorps contre la lipocortine
DE4243375C2 (de)	1998-04-23	Bestimmungsverfahren zur Bestimmung von Antikörpern in biologischen Flüssigkeiten
EP1556697B1 (fr)	2007-10-03	Agents et methodes de diagnostic d'une infection a treponemes